The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed allegations that it has secretly banned the sale and use of Amoxicillin in Nigeria.
Mojisola Adeyeye, the director-general/chief executive officer of NAFDAC, in a statement on Monday, made this known in reaction to a viral video alleging that the agency has secretly banned the sale and use of Amoxicillin in Nigeria.
In its statement, NAFDAC described the claim as false and without factual basis.
“NAFDAC has not banned Amoxicillin in Nigeria, either secretly or openly. As a responsible regulatory authority, the agency publicly notifies Nigerians of any regulatory actions through official channels.
“NAFDAC alerts the public through its recalls, safety alerts, blacklists, and other safety notices of any substandard, falsified, or affected products requiring regulatory action,” the statement said.
The agency explained that these safety communications clearly outline the specific product names, batch numbers, manufacturers, and the necessary measures to be taken.
“They provide critical information that may impact treatment and diagnostic decisions for healthcare providers and patients.
“Blacklisting, where applicable, involves prohibiting specific companies from the sale, distribution, or use of their products due to safety concerns, regulatory violations, or unethical practices,” the agency said.
Targeted recalls, not a ban
In recent months, NAFDAC said it issued targeted safety alerts on certain brands and batches of Amoxicillin.
READ ALSO: Tinubu vows to defeat terrorism, banditry in Nigeria
It added that in August 2025, Public Alert No. 24/2025 announced the recall of Amoxivue (Amoxicillin) 500mg capsules due to low active pharmaceutical ingredient (API) content.
Similarly, in October 2025, Public Alert No. 34/2025 addressed substandard batches of Astamocil and Astamentin suspensions, while Public Alert No. 35/2025 notified the public of substandard batches of Annmox and Jawamox suspensions.
These actions, it said, were specific to identified products and do not constitute a ban on Amoxicillin.
NAFDAC advised members of the public to disregard the “misleading video” and rely only on verified recalls and safety alerts published on its official website.
NAFDAC reaffirmed its commitment to safeguarding public health through transparent, science-based regulatory actions.
